



## **IBA to Present at Jefferies 2016 Annual Healthcare Conference on Wednesday 16 November**

### **Third quarter trading update to be announced that morning**

**Louvain-la-Neuve, Belgium, 25<sup>th</sup> October 2016 - IBA (Ion Beam Applications S.A.),** the world's leading provider of proton therapy solutions for the treatment of cancer, today announces that Jean-Marc Bothy, Chief Strategy Officer, will be presenting at the Jefferies 2016 Global Healthcare Conference at the Waldorf Hilton Hotel, London, on Wednesday 16 November.

The Company will announce its third quarter trading update at 0700 CET on Wednesday 16 November.

- END -

#### **Notes to Editors**

##### **About IBA**

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,400 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com)



For further information please contact:

**IBA**

**Jean-Marc Bothy**

**Chief Strategy Officer**

**Soumya Chandramouli**

**Chief Financial Officer**

+32 10 475 890

[Investorrelations@iba-group.com](mailto:Investorrelations@iba-group.com)

**Thomas Ralet**

Vice-President Corporate Communication

+32 10 475 890

[thomas.ralet@iba-group.com](mailto:thomas.ralet@iba-group.com)

**For media and investor enquiries:**

**Consilium Strategic Communications**

Jonathan Birt, Matthew Neal, Ivar Milligan

+44 (0) 20 3709 5700

[IBA@consilium-comms.com](mailto:IBA@consilium-comms.com)

**Rx Communications Group (US)**

Melody Carey

+1 917 322 2571

[mcarey@RxIR.com](mailto:mcarey@RxIR.com)